|Chemical and physical data|
|Molar mass||525.56 g/mol|
|3D model (Jmol)|
|(what is this?)|
It is being developed by Merck & Co. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015. In 2014 Cowen and Co predicted odanacatib will generate a billion US$ per year in sales by 2020.
This drug was developed at Merck Frosst in Montreal.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 60" (PDF). World Health Organization. 2008. p. 239. Retrieved 11 November 2016.
- Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care. 2 (3): 218–22. PMID 18685424. doi:10.1097/SPC.0b013e32830baea9.
- Gauthier JY, Chauret N, Cromlish W, et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. PMID 18226527. doi:10.1016/j.bmcl.2007.12.047.
- "Merck to seek approval of osteoporosis drug, cites safety risks". Reuters. 2014-05-06.
- "Merck Provides Update on Odanacatib Development Program". Business Wire. 2016-09-02. Archived from the original on 2016-09-03. Retrieved 2016-09-30.
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|